Inherited Retinal Dystrophy

Mendelian MONDO:0019118 Pathograph 4 Show in embeddings browser Ophthalmological Disease Retinal Degeneration

Inherited retinal dystrophies (IRDs) are a large, clinically and genetically heterogeneous group of degenerative diseases of the retina caused by pathogenic variants in any of more than 280 genes. As a Mendelian grouping term, IRD encompasses progressive degeneration of photoreceptors and/or the retinal pigment epithelium (RPE), leading to visual impairment that ranges from congenital blindness to slowly progressive night blindness and central vision loss. The unifying pathophysiology is dysfunction of one of a small number of shared retinal processes - phototransduction, the retinoid (visual) cycle, photoreceptor outer-segment structure and ciliary transport, RPE metabolism and phagocytosis, RNA splicing, or cellular homeostasis - culminating in photoreceptor cell death. Major clinical subtypes include retinitis pigmentosa (rod-predominant), Leber congenital amaurosis (severe congenital onset), cone-rod dystrophy (cone-predominant), and choroideremia (X-linked chorioretinal degeneration). IRDs collectively are a leading cause of inherited blindness in working-age adults.

Ask OpenScientist

Ask a research question about Inherited Retinal Dystrophy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

👪

Inheritance

Autosomal recessive inheritance HP:0000007

Autosomal recessive inheritance

Autosomal dominant inheritance HP:0000006

Autosomal dominant inheritance

X-linked inheritance HP:0001417

X-linked inheritance

◆

Subtypes

Retinitis Pigmentosa MONDO:0019200

The most common IRD; a rod-cone dystrophy beginning with rod photoreceptor degeneration producing night blindness and progressive peripheral (mid-peripheral) visual field constriction, followed by cone involvement and eventual central vision loss. Hallmark fundus findings are bone-spicule pigmentation, attenuated retinal vessels, and waxy disc pallor. Inherited as autosomal recessive, autosomal dominant, or X-linked, and caused by variants in dozens of genes (e.g., RHO, USH2A, RPGR).

Show evidence (1 reference)

PMID:17113430 SUPPORT Human Clinical

"patients typically lose night vision in adolescence, side vision in young adulthood, and central vision in later life because of progressive loss of rod and cone photoreceptor cells"

Defines retinitis pigmentosa as a rod-cone dystrophy with the characteristic sequence of night blindness, peripheral then central vision loss from photoreceptor degeneration.

Leber Congenital Amaurosis MONDO:0018998

The most severe and earliest-onset IRD, presenting in the first year of life with profound visual impairment, nystagmus, sluggish pupillary responses, and a severely reduced or non-recordable electroretinogram. Caused by biallelic variants in genes including RPE65, CEP290, GUCY2D, and CRB1. RPE65-associated LCA is treatable with voretigene neparvovec gene therapy.

Show evidence (1 reference)

PMID:31725251 SUPPORT Human Clinical

"In RPE65-related LCA, onset of visual manifestations frequently occurs in infancy during the first year of life."

GeneReviews documents the congenital/infantile onset that defines Leber congenital amaurosis as the most severe, earliest-onset IRD.

Cone-Rod Dystrophy MONDO:0015993

A cone-predominant IRD in which cone degeneration precedes or exceeds rod loss, producing early central vision loss, reduced visual acuity, photophobia, dyschromatopsia, and central scotomas, with later peripheral field involvement. Caused by variants in genes such as ABCA4, CRX, and GUCY2D.

Choroideremia MONDO:0010557

An X-linked chorioretinal dystrophy caused by loss-of-function variants in CHM, encoding Rab escort protein 1 (REP-1). Affected males develop progressive degeneration of the photoreceptors, RPE, and choriocapillaris, with night blindness in childhood, progressive peripheral field loss, and eventual central vision loss.

Show evidence (2 references)

PMID:20301511 SUPPORT Human Clinical

"Choroideremia (CHM) is characterized by progressive chorioretinal degeneration in affected males and milder signs in heterozygous (carrier) females."

GeneReviews confirms choroideremia as an X-linked progressive chorioretinal degeneration affecting males, with carrier females mildly affected.

PMID:20301511 SUPPORT Human Clinical

"symptoms in affected males evolve from night blindness to peripheral visual field loss, with central vision preserved until late in life"

Documents the clinical course of choroideremia from night blindness through peripheral field loss to late central vision loss.

⚙

Pathophysiology

Photoreceptor Outer Segment and Ciliary Dysfunction

Many IRD genes encode proteins required for the structure and renewal of the photoreceptor outer segment and for protein/lipid transport through the connecting cilium. Defects in outer-segment morphogenesis, disc renewal, or intraflagellar/ciliary transport (e.g., RPGR, CEP290, USH2A) impair phototransduction protein trafficking and outer-segment maintenance, leading to photoreceptor stress and degeneration.

rod photoreceptor CL:0000604 cone photoreceptor CL:0000573

photoreceptor cell outer segment organization GO:0035845

Downstream

Photoreceptor Cell Death

Visual Cycle and Phototransduction Disruption

A second major class of IRD genes encodes components of the retinoid (visual) cycle and the phototransduction cascade. Defects in RPE65, LRAT, RDH genes, RPE-photoreceptor retinoid recycling, or in phototransduction proteins (RHO, GUCY2D, PDE6, CNGA1) impair regeneration of 11-cis-retinal or the conversion of light into a neural signal, causing photoreceptor dysfunction and, when chronic, degeneration.

retinal pigment epithelial cell CL:0002586 rod photoreceptor CL:0000604

visual perception / phototransduction GO:0007601 retinoid metabolic process GO:0001523

Downstream

Photoreceptor Cell Death

Show evidence (1 reference)

PMID:36830640 SUPPORT Other

"have downstream effects in pathways critical to vision, including phototransduction, the visual cycle, photoreceptor development, cellular respiration, and retinal homeostasis"

This mechanistic review identifies phototransduction and the visual cycle among the core pathways disrupted by IRD gene mutations, supporting this node as a shared upstream mechanism.

RPE Dysfunction and Toxic Metabolite Accumulation

The RPE supports photoreceptors via the visual cycle, daily phagocytosis of shed outer-segment discs, and metabolic and barrier functions. In IRDs such as ABCA4-related disease (Stargardt) and choroideremia, defective clearance of retinoid by-products leads to accumulation of toxic bisretinoids (lipofuscin/A2E) in the RPE, RPE cell death, and secondary photoreceptor and choriocapillaris degeneration.

retinal pigment epithelial cell CL:0002586

phagocytosis of shed photoreceptor outer segment discs GO:0006909 ↓ DECREASED

photoreceptor outer segment GO:0001750

Downstream

Photoreceptor Cell Death

Show evidence (1 reference)

PMID:36830640 SUPPORT Other

"These diseases are most often the result of defects in rod and/or cone photoreceptor and retinal pigment epithelium function, development, or both."

This mechanistic review establishes retinal pigment epithelium dysfunction as one of the core defects underlying inherited retinal dystrophies, supporting this RPE node as a shared upstream mechanism.

Photoreceptor Cell Death

The convergent endpoint of all IRD mechanisms is progressive, irreversible apoptotic (and non-apoptotic) death of rod and/or cone photoreceptors, producing the corresponding visual phenotype. Rod loss tends to occur first in rod-cone dystrophies (night blindness, peripheral field loss), while cone loss dominates in cone-rod dystrophies (central acuity and color vision loss).

photoreceptor cell CL:0000210

retinal cell programmed cell death GO:0046666 ↑ INCREASED

Show evidence (2 references)

PMID:17113430 SUPPORT Human Clinical

"progressive loss of rod and cone photoreceptor cells"

Establishes progressive photoreceptor cell death as the convergent mechanism producing vision loss across IRDs.

PMID:40301324 SUPPORT Model Organism

"in genetically and functionally distinct IRD models, common early defects in autophagy and mitochondrial damage exist, triggering photoreceptor cell death by necroptosis in later disease stages"

Single-cell transcriptomic study of humanised IRD mouse models shows autophagy/mitochondrial stress and necroptosis as a convergent, gene-agnostic photoreceptor-death pathway, supporting photoreceptor cell death as the shared endpoint across IRDs.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Eye 7

Night Blindness Nyctalopia HP:0000662

Show evidence (1 reference)

PMID:17113430 SUPPORT Human Clinical

"patients typically lose night vision in adolescence"

Night blindness (nyctalopia) is the characteristic earliest symptom of rod-predominant inherited retinal dystrophy.

Progressive Visual Field Constriction Constriction of peripheral visual field HP:0001133

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:17113430 SUPPORT Human Clinical

"side vision in young adulthood"

Progressive loss of peripheral ("side") vision is a hallmark of retinitis pigmentosa, following the initial night blindness.

Reduced Visual Acuity Reduced visual acuity HP:0007663

Show evidence (1 reference)

PMID:31725251 SUPPORT Human Clinical

"presenting with nyctalopia (i.e., inability or reduced ability to see in dim light or at night) and reduced visual acuity"

GeneReviews documents reduced visual acuity as a presenting feature of RPE65-related early-onset severe retinal dystrophy.

Color Vision Impairment FREQUENT Color vision defect HP:0000551

Show evidence (1 reference)

PMID:37446072 SUPPORT Human Clinical

"Presenting symptoms included nyctalopia (85.4%) photosensitivity/hemeralopia (60.5%), and decreased color vision (55.8%)."

In a cohort of 199 retinitis pigmentosa patients, decreased color vision was a presenting symptom in 55.8%, supporting color vision impairment as a frequent IRD phenotype.

Photophobia Photophobia HP:0000613

Show evidence (1 reference)

PMID:37446072 SUPPORT Human Clinical

"Presenting symptoms included nyctalopia (85.4%) photosensitivity/hemeralopia (60.5%), and decreased color vision (55.8%)."

Photosensitivity/hemeralopia was a presenting symptom in 60.5% of a retinitis pigmentosa cohort, supporting photophobia as a common IRD feature.

Abnormal Electroretinogram Abnormal electroretinogram HP:0000512

Show evidence (1 reference)

PMID:17113430 SUPPORT Human Clinical

"Measures of retinal function, such as the electroretinogram, show that photoreceptor function is diminished generally many years before"

The electroretinogram is a key diagnostic measure that detects diminished photoreceptor function in IRD, often before symptoms arise.

Nystagmus Nystagmus HP:0000639

Other 1

Retinal Pigment Deposits Spicular pigmentation of the retina HP:0007737

🧬

Genetic Associations

RPE65 (Causative)

Gene: RPE65 hgnc:10294

Show evidence (1 reference)

PMID:31725251 SUPPORT Human Clinical

"The three phenotypes of autosomal recessive RPE65-related retinal degeneration, from most severe to mildest, are Leber congenital amaurosis (LCA), early-onset severe retinal dystrophy (EOSRD), and juvenile retinitis pigmentosa (RP)."

Confirms biallelic RPE65 variants cause a spectrum of inherited retinal degeneration spanning LCA, EOSRD, and juvenile RP.

RHO (Causative)

Gene: RHO hgnc:10012

ABCA4 (Causative)

Gene: ABCA4 hgnc:34

RPGR (Causative)

Gene: RPGR hgnc:10295

USH2A (Causative)

Gene: USH2A hgnc:12601

CHM (Causative)

Gene: CHM hgnc:1940

💊

Medical Actions

Voretigene Neparvovec Gene Therapy

Action: gene therapy MAXO:0001001

Subretinal AAV2-mediated gene-augmentation therapy delivering a functional RPE65 cDNA, approved for biallelic RPE65-mutation-associated retinal dystrophy. Improves functional vision and light sensitivity.

Show evidence (1 reference)

PMID:28712537 SUPPORT Human Clinical

"At 1 year, mean bilateral MLMT change score was 1·8 (SD 1·1) light levels in the intervention group versus 0·2 (1·0) in the control group"

The pivotal phase 3 randomised controlled trial demonstrated that voretigene neparvovec improved functional vision (multi-luminance mobility testing) in RPE65-mediated inherited retinal dystrophy.

Vitamin A Supplementation

Action: dietary intervention MAXO:0000088

Historically used dietary intervention proposed to slow electroretinographic decline in some forms of retinitis pigmentosa; benefit is modest and contraindicated in ABCA4-related (Stargardt) disease.

Show evidence (1 reference)

PMID:17113430 PARTIAL Human Clinical

"nutritional interventions, including vitamin A palmitate and omega-3-rich fish, slow progression of disease in many patients"

Controlled-trial data cited in this Seminar indicate vitamin A palmitate and omega-3 supplementation modestly slow disease progression in retinitis pigmentosa; classified PARTIAL because benefit is limited and not applicable to all IRD subtypes (e.g., ABCA4-related disease).

Low Vision Rehabilitation

Action: rehabilitation Ontology label: Rehabilitation NCIT:C15315

Supportive care including low-vision aids, orientation and mobility training, and visual rehabilitation to maximize residual function.

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Genetic counseling and molecular diagnosis are core components of IRD management, informing prognosis, inheritance-based recurrence risk, family planning, and eligibility for gene-specific therapies and trials.

Show evidence (1 reference)

PMID:31725251 SUPPORT Human Clinical

"GENETIC COUNSELING: RPE65-related retinal degeneration is inherited in an autosomal recessive manner."

GeneReviews includes a dedicated genetic counseling section for RPE65-related retinal degeneration, reflecting genetic counseling as a core component of inherited retinal dystrophy management.

{ }

Source YAML

click to show

name: Inherited Retinal Dystrophy
creation_date: "2026-06-08T00:00:00Z"
category: Mendelian
description: >-
  Inherited retinal dystrophies (IRDs) are a large, clinically and genetically
  heterogeneous group of degenerative diseases of the retina caused by
  pathogenic variants in any of more than 280 genes. As a Mendelian grouping
  term, IRD encompasses progressive degeneration of photoreceptors and/or the
  retinal pigment epithelium (RPE), leading to visual impairment that ranges
  from congenital blindness to slowly progressive night blindness and central
  vision loss. The unifying pathophysiology is dysfunction of one of a small
  number of shared retinal processes - phototransduction, the retinoid
  (visual) cycle, photoreceptor outer-segment structure and ciliary transport,
  RPE metabolism and phagocytosis, RNA splicing, or cellular homeostasis -
  culminating in photoreceptor cell death. Major clinical subtypes include
  retinitis pigmentosa (rod-predominant), Leber congenital amaurosis
  (severe congenital onset), cone-rod dystrophy (cone-predominant), and
  choroideremia (X-linked chorioretinal degeneration). IRDs collectively are a
  leading cause of inherited blindness in working-age adults.
disease_term:
  preferred_term: inherited retinal dystrophy
  term:
    id: MONDO:0019118
    label: inherited retinal dystrophy
synonyms:
- hereditary retinal dystrophy
- inherited retinal disease
- retinal dystrophy
- hereditary retinal degeneration
references:
- reference: PMID:30285347
  title: "Nonsyndromic Leber Congenital Amaurosis / Early-Onset Severe Retinal Dystrophy Overview."
  tags:
  - GeneReviews
- reference: PMID:31725251
  title: "Autosomal Recessive RPE65-Related Retinal Degeneration."
  tags:
  - GeneReviews
- reference: PMID:20301511
  title: "Choroideremia."
  tags:
  - GeneReviews
parents:
- Ophthalmological Disease
- Retinal Degeneration
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
- name: Autosomal dominant inheritance
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
- name: X-linked inheritance
  inheritance_term:
    preferred_term: X-linked inheritance
    term:
      id: HP:0001417
      label: X-linked inheritance

epidemiology:
- name: Leading cause of inherited blindness
  description: >-
    Inherited retinal diseases are collectively a leading cause of blindness,
    particularly in working-age adults, and their genetic heterogeneity is the
    principal barrier to therapy development.
  evidence:
  - reference: PMID:40301324
    reference_title: "Autophagy disruption and mitochondrial stress precede photoreceptor necroptosis in multiple mouse models of inherited retinal disorders."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Inherited retinal diseases (IRDs) are a leading cause of blindness worldwide."
    explanation: >-
      Confirms IRDs collectively as a leading worldwide cause of blindness.
- name: Childhood-to-adolescence onset and marked heterogeneity
  description: >-
    Non-syndromic IRDs such as retinitis pigmentosa and Leber congenital
    amaurosis typically present between early childhood and late adolescence and
    are highly genetically and phenotypically heterogeneous.
  evidence:
  - reference: PMID:37525225
    reference_title: "A multidisciplinary approach to inherited retinal dystrophies from diagnosis to initial care: a narrative review with inputs from clinical practice."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Non-syndromic inherited retinal dystrophies (IRDs) such as retinitis pigmentosa or Leber congenital amaurosis generally manifest between early childhood and late adolescence"
    explanation: >-
      Documents the typical childhood-to-adolescence onset window across the
      major non-syndromic IRD subtypes.

prevalence:
- population: Global, all inherited retinal dystrophies combined
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_low: 25.0
  rate_high: 50.0
  percentage: 1 in 2,000 to 1 in 4,000
  notes: >-
    Collectively, inherited retinal dystrophies are estimated to affect
    approximately 1 in 2,000 to 1 in 4,000 people worldwide. Retinitis
    pigmentosa, the most common subtype, accounts for a large share of this
    burden.
  evidence:
  - reference: PMID:38317096
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Inherited retinal degenerations (IRDs) are a group of rare genetic conditions affecting retina of the eye that range in prevalence from 1 in 2000 to 1 in 4000 people globally."
    explanation: >-
      A systematic review provides the consolidated global prevalence range of
      1 in 2,000 to 1 in 4,000 for inherited retinal dystrophies.

has_subtypes:
- name: RP
  display_name: Retinitis Pigmentosa
  subtype_term:
    preferred_term: retinitis pigmentosa
    term:
      id: MONDO:0019200
      label: retinitis pigmentosa
  description: >-
    The most common IRD; a rod-cone dystrophy beginning with rod photoreceptor
    degeneration producing night blindness and progressive peripheral
    (mid-peripheral) visual field constriction, followed by cone involvement and
    eventual central vision loss. Hallmark fundus findings are bone-spicule
    pigmentation, attenuated retinal vessels, and waxy disc pallor. Inherited as
    autosomal recessive, autosomal dominant, or X-linked, and caused by variants
    in dozens of genes (e.g., RHO, USH2A, RPGR).
  evidence:
  - reference: PMID:17113430
    reference_title: "Retinitis pigmentosa."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients typically lose night vision in adolescence, side vision in young adulthood, and central vision in later life because of progressive loss of rod and cone photoreceptor cells"
    explanation: >-
      Defines retinitis pigmentosa as a rod-cone dystrophy with the characteristic
      sequence of night blindness, peripheral then central vision loss from
      photoreceptor degeneration.

- name: LCA
  display_name: Leber Congenital Amaurosis
  subtype_term:
    preferred_term: Leber congenital amaurosis
    term:
      id: MONDO:0018998
      label: Leber congenital amaurosis
  description: >-
    The most severe and earliest-onset IRD, presenting in the first year of life
    with profound visual impairment, nystagmus, sluggish pupillary responses, and
    a severely reduced or non-recordable electroretinogram. Caused by biallelic
    variants in genes including RPE65, CEP290, GUCY2D, and CRB1. RPE65-associated
    LCA is treatable with voretigene neparvovec gene therapy.
  evidence:
  - reference: PMID:31725251
    reference_title: "Autosomal Recessive RPE65-Related Retinal Degeneration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In RPE65-related LCA, onset of visual manifestations frequently occurs in infancy during the first year of life."
    explanation: >-
      GeneReviews documents the congenital/infantile onset that defines Leber
      congenital amaurosis as the most severe, earliest-onset IRD.

- name: Cone-Rod Dystrophy
  display_name: Cone-Rod Dystrophy
  subtype_term:
    preferred_term: cone-rod dystrophy
    term:
      id: MONDO:0015993
      label: cone-rod dystrophy
  description: >-
    A cone-predominant IRD in which cone degeneration precedes or exceeds rod
    loss, producing early central vision loss, reduced visual acuity,
    photophobia, dyschromatopsia, and central scotomas, with later peripheral
    field involvement. Caused by variants in genes such as ABCA4, CRX, and GUCY2D.

- name: Choroideremia
  display_name: Choroideremia
  subtype_term:
    preferred_term: choroideremia
    term:
      id: MONDO:0010557
      label: choroideremia
  description: >-
    An X-linked chorioretinal dystrophy caused by loss-of-function variants in
    CHM, encoding Rab escort protein 1 (REP-1). Affected males develop progressive
    degeneration of the photoreceptors, RPE, and choriocapillaris, with night
    blindness in childhood, progressive peripheral field loss, and eventual
    central vision loss.
  evidence:
  - reference: PMID:20301511
    reference_title: "Choroideremia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Choroideremia (CHM) is characterized by progressive chorioretinal degeneration in affected males and milder signs in heterozygous (carrier) females."
    explanation: >-
      GeneReviews confirms choroideremia as an X-linked progressive chorioretinal
      degeneration affecting males, with carrier females mildly affected.
  - reference: PMID:20301511
    reference_title: "Choroideremia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "symptoms in affected males evolve from night blindness to peripheral visual field loss, with central vision preserved until late in life"
    explanation: >-
      Documents the clinical course of choroideremia from night blindness through
      peripheral field loss to late central vision loss.

pathophysiology:
- name: Photoreceptor Outer Segment and Ciliary Dysfunction
  description: >-
    Many IRD genes encode proteins required for the structure and renewal of the
    photoreceptor outer segment and for protein/lipid transport through the
    connecting cilium. Defects in outer-segment morphogenesis, disc renewal, or
    intraflagellar/ciliary transport (e.g., RPGR, CEP290, USH2A) impair
    phototransduction protein trafficking and outer-segment maintenance, leading
    to photoreceptor stress and degeneration.
  cell_types:
  - preferred_term: rod photoreceptor
    term:
      id: CL:0000604
      label: retinal rod cell
  - preferred_term: cone photoreceptor
    term:
      id: CL:0000573
      label: retinal cone cell
  biological_processes:
  - preferred_term: photoreceptor cell outer segment organization
    term:
      id: GO:0035845
      label: photoreceptor cell outer segment organization
  downstream:
  - target: Photoreceptor Cell Death

- name: Visual Cycle and Phototransduction Disruption
  description: >-
    A second major class of IRD genes encodes components of the retinoid
    (visual) cycle and the phototransduction cascade. Defects in RPE65, LRAT,
    RDH genes, RPE-photoreceptor retinoid recycling, or in phototransduction
    proteins (RHO, GUCY2D, PDE6, CNGA1) impair regeneration of 11-cis-retinal
    or the conversion of light into a neural signal, causing photoreceptor
    dysfunction and, when chronic, degeneration.
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  - preferred_term: rod photoreceptor
    term:
      id: CL:0000604
      label: retinal rod cell
  biological_processes:
  - preferred_term: visual perception / phototransduction
    term:
      id: GO:0007601
      label: visual perception
  - preferred_term: retinoid metabolic process
    term:
      id: GO:0001523
      label: retinoid metabolic process
  evidence:
  - reference: PMID:36830640
    reference_title: "Cellular and Molecular Mechanisms of Pathogenesis Underlying Inherited Retinal Dystrophies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "have downstream effects in pathways critical to vision, including phototransduction, the visual cycle, photoreceptor development, cellular respiration, and retinal homeostasis"
    explanation: >-
      This mechanistic review identifies phototransduction and the visual cycle
      among the core pathways disrupted by IRD gene mutations, supporting this
      node as a shared upstream mechanism.
  downstream:
  - target: Photoreceptor Cell Death

- name: RPE Dysfunction and Toxic Metabolite Accumulation
  description: >-
    The RPE supports photoreceptors via the visual cycle, daily phagocytosis of
    shed outer-segment discs, and metabolic and barrier functions. In IRDs such
    as ABCA4-related disease (Stargardt) and choroideremia, defective clearance
    of retinoid by-products leads to accumulation of toxic bisretinoids
    (lipofuscin/A2E) in the RPE, RPE cell death, and secondary photoreceptor
    and choriocapillaris degeneration.
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  cellular_components:
  - preferred_term: photoreceptor outer segment
    term:
      id: GO:0001750
      label: photoreceptor outer segment
  biological_processes:
  - preferred_term: phagocytosis of shed photoreceptor outer segment discs
    term:
      id: GO:0006909
      label: phagocytosis
    modifier: DECREASED
  evidence:
  - reference: PMID:36830640
    reference_title: "Cellular and Molecular Mechanisms of Pathogenesis Underlying Inherited Retinal Dystrophies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "These diseases are most often the result of defects in rod and/or cone photoreceptor and retinal pigment epithelium function, development, or both."
    explanation: >-
      This mechanistic review establishes retinal pigment epithelium dysfunction
      as one of the core defects underlying inherited retinal dystrophies,
      supporting this RPE node as a shared upstream mechanism.
  downstream:
  - target: Photoreceptor Cell Death

- name: Photoreceptor Cell Death
  description: >-
    The convergent endpoint of all IRD mechanisms is progressive, irreversible
    apoptotic (and non-apoptotic) death of rod and/or cone photoreceptors,
    producing the corresponding visual phenotype. Rod loss tends to occur first
    in rod-cone dystrophies (night blindness, peripheral field loss), while cone
    loss dominates in cone-rod dystrophies (central acuity and color vision loss).
  evidence:
  - reference: PMID:17113430
    reference_title: "Retinitis pigmentosa."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "progressive loss of rod and cone photoreceptor cells"
    explanation: >-
      Establishes progressive photoreceptor cell death as the convergent
      mechanism producing vision loss across IRDs.
  - reference: PMID:40301324
    reference_title: "Autophagy disruption and mitochondrial stress precede photoreceptor necroptosis in multiple mouse models of inherited retinal disorders."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "in genetically and functionally distinct IRD models, common early defects in autophagy and mitochondrial damage exist, triggering photoreceptor cell death by necroptosis in later disease stages"
    explanation: >-
      Single-cell transcriptomic study of humanised IRD mouse models shows
      autophagy/mitochondrial stress and necroptosis as a convergent, gene-agnostic
      photoreceptor-death pathway, supporting photoreceptor cell death as the
      shared endpoint across IRDs.
  cell_types:
  - preferred_term: photoreceptor cell
    term:
      id: CL:0000210
      label: photoreceptor cell
  biological_processes:
  - preferred_term: retinal cell programmed cell death
    term:
      id: GO:0046666
      label: retinal cell programmed cell death
    modifier: INCREASED

phenotypes:
- category: Clinical
  name: Night Blindness
  description: >-
    Impaired vision in dim light (nyctalopia), typically the earliest symptom of
    rod-predominant IRDs such as retinitis pigmentosa and choroideremia.
  phenotype_term:
    preferred_term: Nyctalopia
    term:
      id: HP:0000662
      label: Nyctalopia
  evidence:
  - reference: PMID:17113430
    reference_title: "Retinitis pigmentosa."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients typically lose night vision in adolescence"
    explanation: >-
      Night blindness (nyctalopia) is the characteristic earliest symptom of
      rod-predominant inherited retinal dystrophy.

- category: Clinical
  name: Progressive Visual Field Constriction
  description: >-
    Progressive loss of peripheral visual field ("tunnel vision") from
    mid-peripheral rod degeneration, characteristic of retinitis pigmentosa.
  phenotype_term:
    preferred_term: Constriction of peripheral visual field
    term:
      id: HP:0001133
      label: Constriction of peripheral visual field
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:17113430
    reference_title: "Retinitis pigmentosa."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "side vision in young adulthood"
    explanation: >-
      Progressive loss of peripheral ("side") vision is a hallmark of retinitis
      pigmentosa, following the initial night blindness.

- category: Clinical
  name: Reduced Visual Acuity
  description: >-
    Loss of central visual acuity, occurring early in cone-rod dystrophy and
    Leber congenital amaurosis and later in rod-cone dystrophy.
  phenotype_term:
    preferred_term: Reduced visual acuity
    term:
      id: HP:0007663
      label: Reduced visual acuity
  evidence:
  - reference: PMID:31725251
    reference_title: "Autosomal Recessive RPE65-Related Retinal Degeneration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "presenting with nyctalopia (i.e., inability or reduced ability to see in dim light or at night) and reduced visual acuity"
    explanation: >-
      GeneReviews documents reduced visual acuity as a presenting feature of
      RPE65-related early-onset severe retinal dystrophy.

- category: Clinical
  name: Color Vision Impairment
  description: >-
    Impaired color discrimination (dyschromatopsia), a prominent feature of
    cone-predominant and mixed IRDs and a frequent presenting symptom in
    retinitis pigmentosa cohorts.
  phenotype_term:
    preferred_term: Color vision impairment
    term:
      id: HP:0000551
      label: Color vision defect
  frequency: FREQUENT
  evidence:
  - reference: PMID:37446072
    reference_title: "Clinical Characteristics and Genetic Variants of a Large Cohort of Patients with Retinitis Pigmentosa Using Multimodal Imaging and Next Generation Sequencing."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Presenting symptoms included nyctalopia (85.4%) photosensitivity/hemeralopia (60.5%), and decreased color vision (55.8%)."
    explanation: >-
      In a cohort of 199 retinitis pigmentosa patients, decreased color vision
      was a presenting symptom in 55.8%, supporting color vision impairment as a
      frequent IRD phenotype.

- category: Clinical
  name: Photophobia
  description: >-
    Light sensitivity, common in cone-predominant dystrophies.
  phenotype_term:
    preferred_term: Photophobia
    term:
      id: HP:0000613
      label: Photophobia
  evidence:
  - reference: PMID:37446072
    reference_title: "Clinical Characteristics and Genetic Variants of a Large Cohort of Patients with Retinitis Pigmentosa Using Multimodal Imaging and Next Generation Sequencing."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Presenting symptoms included nyctalopia (85.4%) photosensitivity/hemeralopia (60.5%), and decreased color vision (55.8%)."
    explanation: >-
      Photosensitivity/hemeralopia was a presenting symptom in 60.5% of a
      retinitis pigmentosa cohort, supporting photophobia as a common IRD
      feature.

- category: Clinical
  name: Abnormal Electroretinogram
  description: >-
    Reduced or non-recordable rod and/or cone responses on electroretinography,
    a key diagnostic feature reflecting photoreceptor dysfunction; severely
    reduced or extinguished in Leber congenital amaurosis.
  phenotype_term:
    preferred_term: Abnormal electroretinogram
    term:
      id: HP:0000512
      label: Abnormal electroretinogram
  evidence:
  - reference: PMID:17113430
    reference_title: "Retinitis pigmentosa."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Measures of retinal function, such as the electroretinogram, show that photoreceptor function is diminished generally many years before"
    explanation: >-
      The electroretinogram is a key diagnostic measure that detects diminished
      photoreceptor function in IRD, often before symptoms arise.

- category: Clinical
  name: Retinal Pigment Deposits
  description: >-
    Bone-spicule intraretinal pigment migration and RPE changes, a hallmark
    fundus finding of retinitis pigmentosa.
  phenotype_term:
    preferred_term: Bone spicule-like pigmentary changes
    term:
      id: HP:0007737
      label: Spicular pigmentation of the retina

- category: Clinical
  name: Nystagmus
  description: >-
    Involuntary rhythmic eye movements, characteristic of early-onset severe
    disease such as Leber congenital amaurosis.
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus

genetic:
- name: RPE65
  features: >-
    RPE65 encodes the retinoid isomerohydrolase of the visual cycle; biallelic
    loss-of-function variants cause early-onset severe IRD / Leber congenital
    amaurosis, treatable with voretigene neparvovec gene therapy.
  gene_term:
    preferred_term: RPE65
    term:
      id: hgnc:10294
      label: RPE65
  association: Causative
  evidence:
  - reference: PMID:31725251
    reference_title: "Autosomal Recessive RPE65-Related Retinal Degeneration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The three phenotypes of autosomal recessive RPE65-related retinal degeneration, from most severe to mildest, are Leber congenital amaurosis (LCA), early-onset severe retinal dystrophy (EOSRD), and juvenile retinitis pigmentosa (RP)."
    explanation: >-
      Confirms biallelic RPE65 variants cause a spectrum of inherited retinal
      degeneration spanning LCA, EOSRD, and juvenile RP.

- name: RHO
  features: >-
    RHO encodes rhodopsin, the rod visual pigment; variants are a common cause of
    autosomal dominant retinitis pigmentosa (and a recessive form).
  gene_term:
    preferred_term: RHO
    term:
      id: hgnc:10012
      label: RHO
  association: Causative

- name: ABCA4
  features: >-
    ABCA4 encodes the photoreceptor flippase that clears retinoid by-products;
    biallelic variants cause Stargardt disease and a spectrum of cone-rod and
    rod-cone dystrophies.
  gene_term:
    preferred_term: ABCA4
    term:
      id: hgnc:34
      label: ABCA4
  association: Causative

- name: RPGR
  features: >-
    RPGR encodes the retinitis pigmentosa GTPase regulator at the connecting
    cilium; variants cause the most common form of X-linked retinitis pigmentosa.
  gene_term:
    preferred_term: RPGR
    term:
      id: hgnc:10295
      label: RPGR
  association: Causative

- name: USH2A
  features: >-
    USH2A encodes usherin; variants cause autosomal recessive retinitis
    pigmentosa (non-syndromic) and Usher syndrome type 2 (with hearing loss).
  gene_term:
    preferred_term: USH2A
    term:
      id: hgnc:12601
      label: USH2A
  association: Causative

- name: CHM
  features: >-
    CHM encodes Rab escort protein 1 (REP-1); loss-of-function variants cause
    X-linked choroideremia.
  gene_term:
    preferred_term: CHM
    term:
      id: hgnc:1940
      label: CHM
  association: Causative

treatments:
- name: Voretigene Neparvovec Gene Therapy
  therapeutic_modality: GENE_THERAPY
  description: >-
    Subretinal AAV2-mediated gene-augmentation therapy delivering a functional
    RPE65 cDNA, approved for biallelic RPE65-mutation-associated retinal
    dystrophy. Improves functional vision and light sensitivity.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  evidence:
  - reference: PMID:28712537
    reference_title: "Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At 1 year, mean bilateral MLMT change score was 1·8 (SD 1·1) light levels in the intervention group versus 0·2 (1·0) in the control group"
    explanation: >-
      The pivotal phase 3 randomised controlled trial demonstrated that voretigene
      neparvovec improved functional vision (multi-luminance mobility testing) in
      RPE65-mediated inherited retinal dystrophy.

- name: Vitamin A Supplementation
  description: >-
    Historically used dietary intervention proposed to slow electroretinographic
    decline in some forms of retinitis pigmentosa; benefit is modest and
    contraindicated in ABCA4-related (Stargardt) disease.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:17113430
    reference_title: "Retinitis pigmentosa."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "nutritional interventions, including vitamin A palmitate and omega-3-rich fish, slow progression of disease in many patients"
    explanation: >-
      Controlled-trial data cited in this Seminar indicate vitamin A palmitate and
      omega-3 supplementation modestly slow disease progression in retinitis
      pigmentosa; classified PARTIAL because benefit is limited and not applicable
      to all IRD subtypes (e.g., ABCA4-related disease).

- name: Low Vision Rehabilitation
  description: >-
    Supportive care including low-vision aids, orientation and mobility training,
    and visual rehabilitation to maximize residual function.
  treatment_term:
    preferred_term: rehabilitation
    term:
      id: NCIT:C15315
      label: Rehabilitation

- name: Genetic Counseling
  description: >-
    Genetic counseling and molecular diagnosis are core components of IRD
    management, informing prognosis, inheritance-based recurrence risk, family
    planning, and eligibility for gene-specific therapies and trials.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:31725251
    reference_title: "Autosomal Recessive RPE65-Related Retinal Degeneration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GENETIC COUNSELING: RPE65-related retinal degeneration is inherited in an autosomal recessive manner."
    explanation: >-
      GeneReviews includes a dedicated genetic counseling section for
      RPE65-related retinal degeneration, reflecting genetic counseling as a
      core component of inherited retinal dystrophy management.

📚

References & Deep Research

References

PMID:30285347

Nonsyndromic Leber Congenital Amaurosis / Early-Onset Severe Retinal Dystrophy Overview.

No top-level findings curated for this source.

PMID:31725251

Autosomal Recessive RPE65-Related Retinal Degeneration.

No top-level findings curated for this source.

PMID:20301511

Choroideremia.

No top-level findings curated for this source.

Deep Research

Falcon ▸

1. Disease Information

Edison Scientific Literature 76 citations 2026-06-08T10:21:32.604198

1. Disease Information

1.1 Overview (current understanding)

Inherited retinal dystrophies (IRDs; also commonly termed inherited retinal degenerations/diseases) are a group of rare, typically progressive disorders characterized by dysfunction and eventual loss of photoreceptors (rods and/or cones) and frequently retinal pigment epithelium (RPE) involvement, leading to visual impairment or blindness. IRDs show substantial genetic and phenotypic heterogeneity and overlapping clinical presentations among distinct entities, complicating diagnosis. (murro2023amultidisciplinaryapproach pages 1-2, murro2023amultidisciplinaryapproach pages 2-3)

Abstract-supported quote (definition/impact): Murro et al. describe IRDs as “a group of rare, typically progressive disorders marked by dysfunction and loss of photoreceptors and the retinal pigment epithelium, resulting in marked vision impairment or blindness.” (murro2023amultidisciplinaryapproach pages 1-2)

1.2 Major clinical subtypes / synonyms used in practice

Common IRD entities include: - Retinitis pigmentosa (RP) (most common generalized IRD) (murro2023amultidisciplinaryapproach pages 2-3) - Leber congenital amaurosis (LCA) (severe early-onset IRD of infancy) (murro2023amultidisciplinaryapproach pages 2-3) - Cone dystrophy / cone–rod dystrophy, Stargardt disease (STGD1), Usher syndrome, Bardet–Biedl syndrome, congenital stationary night blindness (CSNB), and many other ocular-only and syndromic forms (malvasi2023genetherapyin pages 2-3, munir2024asystematicreview pages 2-4)

Common umbrella synonyms: - “Inherited retinal dystrophies” - “Inherited retinal degenerations” - “Inherited retinal diseases” These terms are used across aggregated resources and publications (munir2024asystematicreview pages 1-2, murro2023amultidisciplinaryapproach pages 1-2, marques2024currentmanagementof pages 2-3).

1.3 Key identifiers and terminologies

MONDO: MONDO:0019118 (OpenTargets Search: inherited retinal dystrophy,retinitis pigmentosa,Leber congenital amaurosis)
ICD-11/OMIM/Orphanet/MeSH: A 2023 terminology-coverage study shows IRD concepts are variably represented across ICD-11, OMIM, and Orphanet Rare Disease Ontology (ORDO), but specific codes/IDs for the umbrella IRD term were not extractable from the available evidence snippets and should be populated directly from those databases during knowledge-base curation. (malvasi2023genetherapyin pages 18-19)

1.4 Evidence source type

Most information in this report is derived from aggregated disease-level resources (reviews, systematic reviews, cohort studies, trials), not individual EHR-only data. Examples include national surveys (Portugal), systematic review/meta-analyses, genetic-testing cohorts, and prospective trials. (marques2024currentmanagementof pages 3-5, ng2024costofillnessstudiesof pages 1-2)

2. Etiology

2.1 Primary causes

IRDs are primarily caused by pathogenic germline variants in genes critical to retinal development and function, spanning multiple biological pathways (phototransduction, retinoid cycle, cilia/trafficking, disc morphogenesis, RPE phagocytosis). (manley2023cellularandmolecular pages 3-4, manley2023cellularandmolecular pages 4-6)

Inheritance patterns include autosomal recessive (AR), autosomal dominant (AD), X-linked, and mitochondrial inheritance. (murro2023amultidisciplinaryapproach pages 1-2, munir2024asystematicreview pages 1-2)

2.2 Genetic risk factors (causal genes; examples from recent cohorts)

Recent large genetic-testing cohorts emphasize that a limited set of genes contributes disproportionately to diagnoses in some populations: - Taiwanese 319-gene panel cohort (425 probands): most commonly mutated genes among those diagnosed included USH2A (13.7%), EYS (11.3%), CYP4V2 (4.8%), ABCA4 (4.5%), RPGR (3.4%), RP1 (3.1%). (kao2024highlyefficientcapture pages 1-2)

OpenTargets supports strong disease–gene associations for IRD for targets including ABCA4, RPE65, CRB1, PRPH2, GUCY2D, RPGR, RHO (MONDO:0019118 disease node). (OpenTargets Search: inherited retinal dystrophy,retinitis pigmentosa,Leber congenital amaurosis)

2.3 Variant classes contributing to IRD and unsolved cases (2023–2024)

A major theme in 2023–2024 diagnostics is that structural variants (SVs/CNVs) and deep intronic/non-canonical splice variants contribute to molecularly unsolved cases. - In a 2024 NPJ Genomic Medicine WGS study of 271 panel-unsolved IRD patients, WGS produced an additional confirmed genetic diagnosis in 13% (34/271); diagnoses were 7% SV-only, 4% SNV+SV, and 2% intronic variants, with many variants novel. (liu2024wholegenomesequencing pages 1-2) - A 2024 Swiss cohort (WES-unsolved) reported added diagnostic value of WGS of 9.6% (5/66) (jordi2024limitedaddeddiagnostic pages 1-2). - A 2024 clinician-driven exome reanalysis study increased ES diagnostic yield by +8.3 percentage points by incorporating SVs, mitochondrial variants, noncanonical splicing, and updated phenotype data. (surl2024cliniciandrivenreanalysisof pages 1-2)

2.4 Modifier genes / protective factors / gene–environment interactions

Modifier genes / protective variants: Not systematically extractable from the current evidence set; IRD expressivity and phenotype variability are acknowledged (including same gene causing multiple phenotypes), but robust modifier-gene claims require additional dedicated sources (e.g., ClinGen/ClinVar reviews, gene-specific studies). (malvasi2023genetherapyin pages 2-3)
Environmental risk/protective factors: For IRDs as Mendelian disorders, environment is not a primary cause; however, visual-cycle defects can lead to light sensitivity and susceptibility to light damage via toxic aldehyde accumulation in some mechanistic contexts. (manley2023cellularandmolecular pages 19-20)

3. Phenotypes

3.1 Core symptom/sign spectrum

IRDs commonly show (depending on rod vs cone predominance): - Nyctalopia (night blindness) and progressive peripheral field loss typical of rod-cone dystrophy/RP (murro2023amultidisciplinaryapproach pages 2-3) - Reduced visual acuity, photophobia/photosensitivity, color vision impairment, and nystagmus more prominent in cone-predominant and early-onset forms (gong2024infantilenystagmussyndrome—associated pages 2-4)

3.2 Cohort-based phenotype frequencies (example: RP clinic cohort)

A 199-patient RP cohort (University of Minnesota) reported: - Nyctalopia: 85.4% (134/157) - Visual field loss: 92.4% (170/184) - Photosensitivity/hemeralopia: 60.5% (52/86) - Color vision impairment: 55.8% (53/95) - Advanced photoreceptor loss on OCT (ellipsoid zone width <1500 μm): 73.6% (134/182) - FAF abnormalities (macular ring and/or peripheral hypo-AF): 99.0% (191/193) These frequencies are directly useful for knowledge-base phenotype prevalence fields. (sather2023clinicalcharacteristicsand pages 2-4, sather2023clinicalcharacteristicsand pages 1-2)

Supporting visual evidence: The cohort’s clinical characteristics table (counts for onset and imaging categories) is shown in Table 1. (sather2023clinicalcharacteristicsand media ad2e1a73)

3.3 Phenotype characteristics (onset, progression)

Many non-syndromic IRDs manifest between early childhood and late adolescence, though onset varies substantially by gene and subtype. (murro2023amultidisciplinaryapproach pages 1-2)
LCA presents in the first months of life with profound visual deficit and frequently non-detectable ERG. (murro2023amultidisciplinaryapproach pages 2-3, murro2023amultidisciplinaryapproach pages 5-7)

3.4 Quality of life and functional burden

In a large Australian IRD community survey (n=681), median NEI-VFQ-25 was 48 (IQR 38–62) and median EQ-5D-5L utility was 0.81 (VAS 77), consistent with substantial vision-related impairment. (mack2023surveyofperspectives pages 4-6)

3.5 Suggested HPO terms (examples)

Below are suggested HPO mappings commonly applicable across IRD subtypes (with cohort evidence where available): - Nyctalopia – HP:0000662 (85.4% in RP cohort) (sather2023clinicalcharacteristicsand pages 2-4) - Visual field constriction / peripheral visual field loss – e.g., HP:0001132 / HP:0007787 (92.4% visual field loss in RP cohort; progressive concentric loss described in RP) (sather2023clinicalcharacteristicsand pages 2-4, murro2023amultidisciplinaryapproach pages 2-3) - Photophobia / photosensitivity – HP:0000613 (60.5% photosensitivity/hemeralopia in RP cohort) (sather2023clinicalcharacteristicsand pages 2-4) - Abnormal color vision – HP:0000551 (55.8% in RP cohort) (sather2023clinicalcharacteristicsand pages 2-4) - Decreased visual acuity – HP:0007663 (visual acuity worse than 20/80 in ~38–40%) (sather2023clinicalcharacteristicsand pages 1-2) - Abnormal fundus autofluorescence – (phenotypic feature; IRD cohort 99% with ring/peripheral hypo-AF) (sather2023clinicalcharacteristicsand pages 2-4) - Abnormality of the ellipsoid zone / photoreceptor layer – (reduced EZ width <1500 μm in 73.6%) (sather2023clinicalcharacteristicsand pages 2-4) - Cystoid macular edema – HP:0001103 (noted as common OCT finding in RP in review) (malvasi2023genetherapyin pages 18-19)

4. Genetic/Molecular Information

4.1 Causal genes (examples; not exhaustive)

Recent reviews and cohorts support hundreds of causal genes across IRDs (>280–300 genes reported) (munir2024asystematicreview pages 1-2, murro2023amultidisciplinaryapproach pages 5-7). Commonly implicated genes by population and phenotype include: - RP / rod-cone dystrophy: EYS, USH2A, RPGR, RHO, PDE6A/PDE6B, PRPF31 (liu2024wholegenomesequencing pages 1-2, kao2024highlyefficientcapture pages 1-2, munir2024asystematicreview pages 2-4) - LCA / early-onset: RPE65, CEP290, GUCY2D, LCA5 (murro2023amultidisciplinaryapproach pages 2-3, gong2024infantilenystagmussyndrome—associated pages 16-17) - Maculopathies / Stargardt: ABCA4 (munir2024asystematicreview pages 2-4)

4.2 Pathogenic variant types and frequency considerations

In a Pakistan IRD literature synthesis, reported variant classes included missense (41.88%), indels/frameshift (26.35%), nonsense (19.13%), splice site (12.27%), and rare synonymous changes, with strong homozygosity reflecting consanguinity. (munir2024asystematicreview pages 1-2)
2024 WGS work highlights under-detected classes in unresolved patients: SVs and intronic splice variants. (liu2024wholegenomesequencing pages 1-2)

4.3 Somatic vs germline

The reviewed evidence pertains to germline pathogenic variants underlying Mendelian IRDs; somatic mosaic contributions were not extractable from the current sources.

4.4 Epigenetics

Single-cell transcriptomic/epigenomic maps of developing human retina and animal models have been cited as providing mechanistic insights relevant to IRDs, but disease-specific epigenetic signatures were not provided in the accessible excerpts. (duncan2024inheritedretinaldegenerations pages 2-4)

5. Environmental Information

IRDs are primarily genetic disorders. Environmental exposures are generally not causal; however, mechanistic literature indicates that disruption of retinoid handling can produce toxic retinoid intermediate accumulation and increased vulnerability to light damage in some pathways, representing a gene-context-dependent susceptibility rather than a population-level environmental risk factor. (manley2023cellularandmolecular pages 19-20)

6. Mechanism / Pathophysiology

6.1 Affected structures and key causal chains

Core mechanistic theme: gene mutation → dysfunction in photoreceptor/RPE pathways → photoreceptor dysfunction → degeneration → vision loss.

Major mechanistic categories supported by recent reviews: 1. Phototransduction dysfunction (rods/cones) - Mutations in phototransduction components (e.g., RHO, GNAT1/2, PDE6 subunits) can drive misfolding, mislocalization, altered signaling, and toxic cGMP dysregulation, contributing to photoreceptor degeneration. (manley2023cellularandmolecular pages 4-6) 2. Visual cycle / retinoid cycle defects (RPE–photoreceptor interface) - Mutations in visual-cycle genes (e.g., RPE65, LRAT, RLBP1, RBP4, RDH genes) reduce 11-cis retinal regeneration (chromophore deficiency) and can promote toxic aldehyde accumulation, leading to impaired dark adaptation and progressive degeneration. (manley2023cellularandmolecular pages 19-20, manley2023cellularandmolecular pages 18-19) 3. Ciliary transport and protein trafficking defects - Defects in connecting cilium/ciliary trafficking (e.g., RPGR and other ciliary proteins) impair delivery of key proteins to outer segments and can cause early retinal cell death in models. (manley2023cellularandmolecular pages 8-10, manley2023cellularandmolecular pages 3-4) 4. Disc morphogenesis and outer-segment structural maintenance - Mutations in disc-structure genes (e.g., PRPH2, ROM1, PROM1, PCDH21, CFAP418) disrupt disc formation/maintenance, causing protein mislocalization and progressive degeneration. (manley2023cellularandmolecular pages 14-16) 5. RPE phagocytosis/outer-segment renewal defects - Mutations in phagocytosis genes (e.g., MERTK) disrupt daily outer-segment shedding/clearance and lead to toxic buildup. (manley2023cellularandmolecular pages 19-20)

6.2 Cell types (CL suggestions)

Photoreceptor cell (rods and cones) – central effector cells of degeneration (manley2023cellularandmolecular pages 3-4)
Retinal pigment epithelial cell – visual cycle, phagocytosis, lipofuscin/toxic byproducts (manley2023cellularandmolecular pages 19-20)
Müller glial cell – implicated in some visual cycle/retinoid pathways and retinal homeostasis (manley2023cellularandmolecular pages 19-20)

6.3 Anatomical structures (UBERON suggestions)

Retina (UBERON:0000966)
Photoreceptor outer segment (UBERON:0001922) (functional unit emphasized across mechanisms)
Retinal pigment epithelium (UBERON:0000968)

6.4 Pathway/process ontology suggestions (GO terms; examples)

Phototransduction (GO:0007602)
Visual perception (GO:0007601)
Retinoid metabolic process / visual cycle (e.g., GO:0001523 retinoid metabolic process)
Cilium organization (GO:0044782) and intraciliary transport (GO:0044783)
Phagocytosis, engulfment (GO:0006911)

6.5 Recent multi-omics / translational advances (2024)

A 2024 review highlights that single-cell transcriptomic and epigenomic maps of developing human retina and animal models have provided mechanistic insights, and emphasizes the search for shared downstream mechanisms (neuroprotective pathways; outer retinal metabolism) to enable gene-agnostic therapies. (duncan2024inheritedretinaldegenerations pages 2-4)

7. Anatomical Structures Affected

Primary organ/system: eye (retina), with primary involvement of photoreceptors and often RPE (murro2023amultidisciplinaryapproach pages 1-2)
Tissue/cell level: photoreceptors (rod and cone), RPE, and supporting retinal glia (manley2023cellularandmolecular pages 3-4)
Localization: typically bilateral involvement (inherited dystrophies), with progressive outer retinal changes observable on OCT and FAF (murro2023amultidisciplinaryapproach pages 5-7)

8. Temporal Development (Natural history)

Onset: often childhood/adolescence for many non-syndromic generalized photoreceptor dystrophies; LCA in infancy (murro2023amultidisciplinaryapproach pages 1-2, murro2023amultidisciplinaryapproach pages 2-3)
Progression pattern: typically progressive, with rod involvement often preceding cone involvement (night blindness → peripheral constriction → central acuity decline) in RP; other IRDs may be cone-predominant or stationary (CSNB). (murro2023amultidisciplinaryapproach pages 2-3, malvasi2023genetherapyin pages 2-3)

9. Inheritance and Population

9.1 Epidemiology (recent and cohort-based)

Global IRD prevalence estimates: ~1:2,000 to 1:4,000. (munir2024asystematicreview pages 1-2)
RP prevalence: ~1:4,000 worldwide. (murro2023amultidisciplinaryapproach pages 2-3)
Portugal (national survey estimate): 0.031% (~1:3,000). (marques2024currentmanagementof pages 3-5)

9.2 Population genetics and consanguinity

A 2024 Pakistan systematic review (1999–Apr 2023) reported strong consanguinity effects: - ~70% of index cases had consanguineous parents - >95% of cases were recessively inherited - ~88.8% of detected variants were homozygous This emphasizes the role of consanguinity in shaping IRD inheritance patterns and homozygosity in specific populations. (munir2024asystematicreview pages 1-2)

10. Diagnostics

10.1 Clinical and functional testing (recommended workup)

Recent reviews recommend a stepwise diagnostic approach including: - Detailed medical and family history, evaluation for syndromic features, and multidisciplinary assessment (ophthalmology + genetics and other specialties as needed). (murro2023amultidisciplinaryapproach pages 3-5) - Electrophysiology: Full-field ERG (ISCEV-guided) to distinguish rod vs cone disease; FST as alternative when ERG/fixation is limited; mfERG to detect residual function/progression. (murro2023amultidisciplinaryapproach pages 3-5, murro2023amultidisciplinaryapproach pages 5-7) - Imaging: SD-OCT (outer retinal layers, ellipsoid zone, ONL), fundus autofluorescence (RPE/photoreceptor loss patterns; hyper-AF rings), and in some contexts OCT-A. (murro2023amultidisciplinaryapproach pages 3-5, murro2023amultidisciplinaryapproach pages 5-7) - Visual field testing: Goldmann/kinetic perimetry for peripheral loss; microperimetry for central sensitivity (murro2023amultidisciplinaryapproach pages 3-5, heon2023geneticsofretinal pages 4-5)

10.2 Genetic testing strategy and yields (2023–2024)

Targeted multi-gene NGS panels are widely used; one review notes molecular diagnoses can be obtained in up to ~70% but 30–40% remain unsolved. (murro2023amultidisciplinaryapproach pages 5-7)
Large 2024 cohort data demonstrate yields and incremental improvements:
319-gene panel: 68.5% molecular diagnosis in 425 probands (Taiwan). (kao2024highlyefficientcapture pages 1-2)
Genome sequencing in routine care: 57.4% definite diagnosis in 1,000 inherited eye disease probands; SV/non-coding variants comprised 12.7% of observed variants. (weisschuh2024diagnosticgenomesequencing pages 1-2)
Clinician-driven ES reanalysis: improved yield by +8.3 percentage points in 264 IRD patients. (surl2024cliniciandrivenreanalysisof pages 1-2)
WGS in panel-unsolved cases: 13% additional diagnoses in 271 unresolved IRD patients, often via SVs/intronic variants. (liu2024wholegenomesequencing pages 1-2)

10.3 Differential diagnosis

A formal differential list (e.g., acquired retinal degenerations, inflammatory/autoimmune retinopathies, toxic retinopathies) was not explicitly extractable from the retrieved excerpts; however, multidisciplinary evaluation for systemic features and targeted ancillary testing for syndromic IRDs is recommended. (murro2023amultidisciplinaryapproach pages 3-5)

11. Outcome / Prognosis

11.1 Vision-related prognosis

Prognosis is subtype- and gene-dependent; in RP, progressive outer retinal atrophy and field constriction typically worsen over time, with structural correlates on OCT (ellipsoid zone loss/ONL thinning). (malvasi2023genetherapyin pages 18-19)

11.2 Economic and societal burden (recent data)

A 2024 systematic review of cost-of-illness studies found substantial per-patient costs and that non-health (societal) costs dominate: - Annual per-patient totals (standardized): Singapore ~US$6,926; Japan US$20,833; UK US$21,658–36,549; US ~US$33,017–186,051; Canada US$16,470–275,045 (ng2024costofillnessstudiesof pages 1-2) - Non-health costs comprised ~87–98% of total costs in included studies. (ng2024costofillnessstudiesof pages 1-2)

12. Treatment

12.1 Approved gene therapy (real-world implementation)

Voretigene neparvovec (VN; Luxturna) - Indication: IRD due to biallelic RPE65 mutations. - Regulatory history: FDA approval 2017; EMA approval 2018. (testa2024voretigeneneparvovecfor pages 1-2) - Epidemiologic context: biallelic RPE65 mutations estimated to account for ~8% of LCA and ~2% of RP. (testa2024voretigeneneparvovecfor pages 1-2) - Real-world issues: eligibility requires preserved viable retina/photoreceptors, but no single upper limit of degeneration defines eligibility; pediatric patients often have greater potential benefit. (testa2024voretigeneneparvovecfor pages 1-2)

MAXO suggestions (illustrative): - Gene therapy procedure (subretinal delivery) - Genetic counseling - Visual rehabilitation / low-vision support

12.2 Landmark and emerging interventional trials (2024)

RLBP1 gene therapy (AAV8-RLBP1; NCT03374657): Phase 1/2, n=12, subretinal delivery; dose-dependent inflammation responsive to corticosteroids; focal RPE atrophy dose-limiting; significant improvements in dark adaptation across cohorts; one study-drug–related severe vision loss SAE. (kvanta2024interimsafetyand pages 1-2)
CYP4V2 gene replacement in Bietti crystalline dystrophy (rAAV2/8-hCYP4V2; NCT04722107): open-label exploratory trial, n=12; 77.8% BCVA improvement at day 180 (mean +9.0 letters, p=0.021); no treatment-related serious AEs or immune toxicities. (wang2024genereplacementtherapy pages 1-2)

12.3 Clinical trials and real-world endpoints

The pivotal Luxturna Phase 3 trial (NCT00999609) used bilateral multi-luminance mobility testing (MLMT) as the primary efficacy endpoint and also used full-field light sensitivity threshold (FST) and visual acuity among secondary endpoints. (NCT00999609 chunk 1)

Endpoint selection is an ongoing challenge because traditional measures (BCVA, macular OCT) may not capture peripheral, night, contrast, and real-world functional outcomes, motivating inclusion of microperimetry, FST, mobility tests, and patient-reported outcomes. (brar2023genetherapyfor pages 23-25)

12.4 In vivo genome editing (recent implementation example)

The EDIT-101 trial (NCT03872479) is a phase 1/2 open-label CRISPR-based program for CEP290-associated LCA10, with outcomes including safety and a broad set of functional/structural measures (mobility, BCVA, FST, microperimetry, contrast sensitivity, macular thickness, QoL). (NCT03872479 chunk 1)

13. Prevention

13.1 Primary prevention

Primary prevention is limited for Mendelian IRDs, but reproductive risk reduction strategies are standard: - Genetic counseling for affected individuals and families (pre- and post-test counseling recommended). (murro2023amultidisciplinaryapproach pages 7-8) - Carrier testing/cascade testing and reproductive options (prenatal testing/PGT) are implied as key counseling topics, though not detailed in the retrieved excerpts. (murro2023amultidisciplinaryapproach pages 7-8)

13.2 Secondary/tertiary prevention

Early diagnosis and longitudinal monitoring with OCT/FAF/ERG and functional testing to detect treatable complications and identify gene-therapy eligibility windows (especially where preserved photoreceptors remain). (testa2024voretigeneneparvovecfor pages 1-2, murro2023amultidisciplinaryapproach pages 5-7)

14. Other Species / Natural Disease

Naturally occurring retinal dystrophies occur across multiple species and are widely used for translational research, but species-specific natural disease examples were not extractable from the current evidence snippets.

15. Model Organisms

Animal models (including mouse models) have been used to replicate human IRD phenotypes to study mechanisms and develop therapies; mechanistic reviews explicitly refer to mouse evidence for ciliary gene defects leading to retinal cell death (e.g., RPGR). (manley2023cellularandmolecular pages 8-10)

Recent developments and real-world implementation highlights (2023–2024 synthesis)

Genetic testing is becoming more actionable due to therapy and trial eligibility; advanced pipelines and reanalysis improve yields (e.g., +8.3% by clinician-led exome reanalysis). (surl2024cliniciandrivenreanalysisof pages 1-2)
Beyond-exome variants matter: WGS can identify SVs and intronic splice variants missed by panels/WES in a meaningful fraction of unresolved cases (e.g., 13% additional diagnoses in a 271-patient unresolved cohort). (liu2024wholegenomesequencing pages 1-2)
Therapeutic expansion beyond RPE65: 2024 trials report encouraging interim results for visual-cycle gene therapy (RLBP1) and first-in-human gene replacement for CYP4V2-associated disease. (kvanta2024interimsafetyand pages 1-2, wang2024genereplacementtherapy pages 1-2)
Patient/community readiness is high but knowledge gaps persist: 91.6% willingness to accept gene therapy in an Australian survey, but only 28.3% reported good knowledge; internet was the most common information source (49.3%). (mack2023surveyofperspectives pages 2-3)
Societal burden is dominated by non-health costs (87–98% of total), strengthening the case for holistic evaluation of emerging interventions beyond direct healthcare spending. (ng2024costofillnessstudiesof pages 1-2)

Evidence summary tables

Claim/Metric	Value	Population/Study	Publication (year, journal)	URL/DOI
Global IRD prevalence	~1 in 2,000 to 1 in 4,000	General/global IRD estimates (munir2024asystematicreview pages 1-2)	Munir et al. 2024, BMC Ophthalmology	https://doi.org/10.1186/s12886-024-03319-7
RP prevalence	~1:4,000 worldwide	Retinitis pigmentosa, global estimate (murro2023amultidisciplinaryapproach pages 2-3)	Murro et al. 2023, Orphanet Journal of Rare Diseases	https://doi.org/10.1186/s13023-023-02798-z
LCA prevalence	~1/30,000 to 1/81,000; ~5% of IRDs	Leber congenital amaurosis (murro2023amultidisciplinaryapproach pages 2-3, malvasi2023genetherapyin pages 2-3)	Murro et al. 2023, Orphanet Journal of Rare Diseases; Malvasi et al. 2023, IJMS	https://doi.org/10.1186/s13023-023-02798-z; https://doi.org/10.3390/ijms241813756
Stargardt disease prevalence	~1 in 8,000–10,000	STGD1 global estimate (munir2024asystematicreview pages 2-4)	Munir et al. 2024, BMC Ophthalmology	https://doi.org/10.1186/s12886-024-03319-7
Portugal IRD prevalence	0.031% (~1 in 3,000)	Nationwide Portuguese IRD-PT survey, 26 HCP respondents (marques2024currentmanagementof pages 3-5, marques2024currentmanagementof pages 1-2)	Marques et al. 2024, Scientific Reports	https://doi.org/10.1038/s41598-024-72589-4
Portugal biallelic RPE65 prevalence	0.00031% (~1 in 300,000)	Nationwide Portuguese IRD-PT survey (marques2024currentmanagementof pages 1-2)	Marques et al. 2024, Scientific Reports	https://doi.org/10.1038/s41598-024-72589-4
Pakistan consanguinity among IRD index cases	~70%	Pakistani IRD literature review, 1999–2023 (munir2024asystematicreview pages 1-2, munir2024asystematicreview pages 10-12, munir2024asystematicreview pages 9-10)	Munir et al. 2024, BMC Ophthalmology	https://doi.org/10.1186/s12886-024-03319-7
Pakistan recessive inheritance proportion	>95% recessive; ~88.8% homozygous variants	Pakistani IRD literature review (munir2024asystematicreview pages 1-2)	Munir et al. 2024, BMC Ophthalmology	https://doi.org/10.1186/s12886-024-03319-7
Broad NGS panel diagnostic yield	64.3%	1,005 inherited eye disease patients in Poland, 2020–2023 (kao2024highlyefficientcapture pages 1-2)	Matczyńska et al. 2024, Biomedicines	https://doi.org/10.3390/biomedicines12061355
319-gene panel diagnostic yield	68.5% molecular diagnosis; 53.9% resolved	425 Taiwanese IRD probands (kao2024highlyefficientcapture pages 1-2, kao2024highlyefficientcapture pages 2-2)	Kao et al. 2024, NPJ Genomic Medicine	https://doi.org/10.1038/s41525-023-00388-3
smMIPs panel diagnostic yield	56%	1,192 RP/LCA probands, international cohort (surl2024cliniciandrivenreanalysisof pages 1-2)	Panneman et al. 2023, Frontiers in Cell and Developmental Biology	https://doi.org/10.3389/fcell.2023.1112270
Exome sequencing initial diagnostic yield	62.9%	264 Korean IRD patients before reanalysis (surl2024cliniciandrivenreanalysisof pages 1-2)	Surl et al. 2024, JAMA Network Open	https://doi.org/10.1001/jamanetworkopen.2024.14198
Exome reanalysis increment	+8.3 percentage points; final yield ~71.2%	264 Korean IRD patients, clinician-driven ES reanalysis (surl2024cliniciandrivenreanalysisof pages 1-2)	Surl et al. 2024, JAMA Network Open	https://doi.org/10.1001/jamanetworkopen.2024.14198
Genome sequencing yield in routine care	57.4% definite diagnosis; non-coding/SV variants were 12.7% of observed variants	1,000 inherited eye disease probands (IRD/ION), Germany (weisschuh2024diagnosticgenomesequencing pages 1-2)	Weisschuh et al. 2024, Journal of Medical Genetics	https://doi.org/10.1136/jmg-2023-109470
WGS added yield in previously unsolved IRDs	13% additional diagnoses; 7% SV only, 4% SNV+SV, 2% intronic	271 unresolved IRD patients after prior panel screening (liu2024wholegenomesequencing pages 1-2)	Liu et al. 2024, NPJ Genomic Medicine	https://doi.org/10.1038/s41525-024-00391-2
WGS incremental value after prior WES	9.6% added diagnostic value (5/66); overall WGS diagnosis 28.8% (19/66)	66 Swiss index patients unsolved after WES (jordi2024limitedaddeddiagnostic pages 1-2, jordi2024limitedaddeddiagnostic pages 8-9)	Maggi et al. 2024, IJMS	https://doi.org/10.3390/ijms25126540
Gene therapy: AAV8-RLBP1	NCT03374657; n=12; primary endpoints: ocular/systemic safety and dark adaptation recovery; significant improvement in dark adaptation across all dose cohorts; 108 AEs (65 ocular, 43 non-ocular); dose-dependent inflammation responsive to corticosteroids; focal RPE atrophy was dose-limiting toxicity; 1 study-drug–related severe vision loss SAE	Phase 1/2, biallelic RLBP1-associated retinal dystrophy (kvanta2024interimsafetyand pages 1-2)	Kvanta et al. 2024, Nature Communications	https://doi.org/10.1038/s41467-024-51575-4
Gene therapy: rAAV2/8-hCYP4V2 (ZVS101e)	NCT04722107; n=12; endpoints: safety, BCVA, mfERG, microperimetry, VFQ-25; BCVA improved in 77.8% at day 180 (mean +9.0±10.8 letters, p=0.021) and 80% at day 365 (mean +11.0±10.6 letters, p=0.125, 5 eyes assessed); 73 TEAEs, 98.6% mild/moderate; no treatment-related SAEs or immune toxicities	Open-label exploratory trial in Bietti crystalline corneoretinal dystrophy (wang2024genereplacementtherapy pages 1-2)	Wang et al. 2024, Signal Transduction and Targeted Therapy	https://doi.org/10.1038/s41392-024-01806-3

Table: This table compacts high-value evidence for inherited retinal dystrophy across epidemiology, molecular diagnostic yield, and recent interventional trials. It is useful for quickly extracting population-level figures, comparing testing strategies, and summarizing the most recent human gene therapy outcome data.

Key URLs (recent, prioritized)

Munir et al., 2024 (systematic review; epidemiology, consanguinity): https://doi.org/10.1186/s12886-024-03319-7 (Feb 2024) (munir2024asystematicreview pages 1-2)
Marques et al., 2024 (Portugal IRD prevalence survey): https://doi.org/10.1038/s41598-024-72589-4 (Sep 2024) (marques2024currentmanagementof pages 3-5)
Weisschuh et al., 2024 (prospective GS in 1000 inherited eye disease patients): https://doi.org/10.1136/jmg-2023-109470 (Sep 2024) (weisschuh2024diagnosticgenomesequencing pages 1-2)
Surl et al., 2024 (clinician-driven exome reanalysis): https://doi.org/10.1001/jamanetworkopen.2024.14198 (May 2024) (surl2024cliniciandrivenreanalysisof pages 1-2)
Testa et al., 2024 (Luxturna real-world eligibility challenges): https://doi.org/10.1038/s41433-024-03065-6 (Apr 2024) (testa2024voretigeneneparvovecfor pages 1-2)
Kvanta et al., 2024 (AAV8-RLBP1 trial): https://doi.org/10.1038/s41467-024-51575-4 (Sep 2024) (kvanta2024interimsafetyand pages 1-2)
Wang et al., 2024 (CYP4V2 gene replacement trial): https://doi.org/10.1038/s41392-024-01806-3 (Apr 2024) (wang2024genereplacementtherapy pages 1-2)
Ng et al., 2024 (cost-of-illness systematic review): https://doi.org/10.1186/s13023-024-03099-9 (Feb 2024) (ng2024costofillnessstudiesof pages 1-2)
ClinicalTrials.gov Luxturna pivotal trial (RPE65): https://clinicaltrials.gov/study/NCT00999609 (results first posted 2018-03-26) (NCT00999609 chunk 1)
ClinicalTrials.gov EDIT-101 (CEP290): https://clinicaltrials.gov/study/NCT03872479 (first posted 2019) (NCT03872479 chunk 1)

References

(OpenTargets Search: inherited retinal dystrophy,retinitis pigmentosa,Leber congenital amaurosis): Open Targets Query (inherited retinal dystrophy,retinitis pigmentosa,Leber congenital amaurosis, 42 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(murro2023amultidisciplinaryapproach pages 1-2): Vittoria Murro, Sandro Banfi, Francesco Testa, Giancarlo Iarossi, Benedetto Falsini, Andrea Sodi, Sabrina Signorini, Achille Iolascon, Roberta Russo, Dario Pasquale Mucciolo, Roberto Caputo, Giacomo Maria Bacci, Sara Bargiacchi, Simona Turco, Stefania Fortini, and Francesca Simonelli. A multidisciplinary approach to inherited retinal dystrophies from diagnosis to initial care: a narrative review with inputs from clinical practice. Orphanet Journal of Rare Diseases, Jul 2023. URL: https://doi.org/10.1186/s13023-023-02798-z, doi:10.1186/s13023-023-02798-z. This article has 51 citations and is from a peer-reviewed journal.
(munir2024asystematicreview pages 1-2): Asad Munir, Salma Afsar, and Atta Ur Rehman. A systematic review of inherited retinal dystrophies in pakistan: updates from 1999 to april 2023. BMC Ophthalmology, Feb 2024. URL: https://doi.org/10.1186/s12886-024-03319-7, doi:10.1186/s12886-024-03319-7. This article has 18 citations and is from a peer-reviewed journal.
(murro2023amultidisciplinaryapproach pages 2-3): Vittoria Murro, Sandro Banfi, Francesco Testa, Giancarlo Iarossi, Benedetto Falsini, Andrea Sodi, Sabrina Signorini, Achille Iolascon, Roberta Russo, Dario Pasquale Mucciolo, Roberto Caputo, Giacomo Maria Bacci, Sara Bargiacchi, Simona Turco, Stefania Fortini, and Francesca Simonelli. A multidisciplinary approach to inherited retinal dystrophies from diagnosis to initial care: a narrative review with inputs from clinical practice. Orphanet Journal of Rare Diseases, Jul 2023. URL: https://doi.org/10.1186/s13023-023-02798-z, doi:10.1186/s13023-023-02798-z. This article has 51 citations and is from a peer-reviewed journal.
(malvasi2023genetherapyin pages 2-3): Mariaelena Malvasi, Lorenzo Casillo, Filippo Avogaro, Alessandro Abbouda, and Enzo Maria Vingolo. Gene therapy in hereditary retinal dystrophies: the usefulness of diagnostic tools in candidate patient selections. International Journal of Molecular Sciences, 24:13756, Sep 2023. URL: https://doi.org/10.3390/ijms241813756, doi:10.3390/ijms241813756. This article has 26 citations.
(munir2024asystematicreview pages 2-4): Asad Munir, Salma Afsar, and Atta Ur Rehman. A systematic review of inherited retinal dystrophies in pakistan: updates from 1999 to april 2023. BMC Ophthalmology, Feb 2024. URL: https://doi.org/10.1186/s12886-024-03319-7, doi:10.1186/s12886-024-03319-7. This article has 18 citations and is from a peer-reviewed journal.
(marques2024currentmanagementof pages 2-3): João Pedro Marques, Nuno Ferreira, Natacha Moreno, Ana Marta, Sara Vaz-Pereira, Sérgio Estrela-Silva, José Costa, Ana Rocha Cardoso, Pedro Neves, Lilianne Duarte, Dália Meira, Joana Pires, Carlos Menezes, Filipa Rodrigues, Pedro Arede, André Coutinho, Diogo Cabral, Inês Coutinho, Miguel Ribeiro, Marta Macedo, Sérgio Brito, Filipe Isidro, Filipa Gomes Rodrigues, João Paulo Castro Sousa, Marco Marques, Raquel Martins, and Eduardo Silva. Current management of inherited retinal degenerations in portugal (ird-pt survey). Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-72589-4, doi:10.1038/s41598-024-72589-4. This article has 7 citations and is from a peer-reviewed journal.
(malvasi2023genetherapyin pages 18-19): Mariaelena Malvasi, Lorenzo Casillo, Filippo Avogaro, Alessandro Abbouda, and Enzo Maria Vingolo. Gene therapy in hereditary retinal dystrophies: the usefulness of diagnostic tools in candidate patient selections. International Journal of Molecular Sciences, 24:13756, Sep 2023. URL: https://doi.org/10.3390/ijms241813756, doi:10.3390/ijms241813756. This article has 26 citations.
(marques2024currentmanagementof pages 3-5): João Pedro Marques, Nuno Ferreira, Natacha Moreno, Ana Marta, Sara Vaz-Pereira, Sérgio Estrela-Silva, José Costa, Ana Rocha Cardoso, Pedro Neves, Lilianne Duarte, Dália Meira, Joana Pires, Carlos Menezes, Filipa Rodrigues, Pedro Arede, André Coutinho, Diogo Cabral, Inês Coutinho, Miguel Ribeiro, Marta Macedo, Sérgio Brito, Filipe Isidro, Filipa Gomes Rodrigues, João Paulo Castro Sousa, Marco Marques, Raquel Martins, and Eduardo Silva. Current management of inherited retinal degenerations in portugal (ird-pt survey). Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-72589-4, doi:10.1038/s41598-024-72589-4. This article has 7 citations and is from a peer-reviewed journal.
(ng2024costofillnessstudiesof pages 1-2): Qin Xiang Ng, Clarence Ong, Clyve Yu Leon Yaow, Hwei Wuen Chan, Julian Thumboo, Yi Wang, and Gerald Choon Huat Koh. Cost-of-illness studies of inherited retinal diseases: a systematic review. Orphanet Journal of Rare Diseases, Feb 2024. URL: https://doi.org/10.1186/s13023-024-03099-9, doi:10.1186/s13023-024-03099-9. This article has 23 citations and is from a peer-reviewed journal.
(manley2023cellularandmolecular pages 3-4): Andrew Manley, Bahar I. Meshkat, Monica M. Jablonski, and T.J. Hollingsworth. Cellular and molecular mechanisms of pathogenesis underlying inherited retinal dystrophies. Biomolecules, 13:271, Feb 2023. URL: https://doi.org/10.3390/biom13020271, doi:10.3390/biom13020271. This article has 61 citations.
(manley2023cellularandmolecular pages 4-6): Andrew Manley, Bahar I. Meshkat, Monica M. Jablonski, and T.J. Hollingsworth. Cellular and molecular mechanisms of pathogenesis underlying inherited retinal dystrophies. Biomolecules, 13:271, Feb 2023. URL: https://doi.org/10.3390/biom13020271, doi:10.3390/biom13020271. This article has 61 citations.
(kao2024highlyefficientcapture pages 1-2): Hsiao-Jung Kao, Ting-Yi Lin, Feng-Jen Hsieh, Jia-Ying Chien, Erh-Chan Yeh, Wan-Jia Lin, Yi-Hua Chen, Kai-Hsuan Ding, Yu Yang, Sheng-Chu Chi, Ping-Hsing Tsai, Chih-Chien Hsu, De-Kuang Hwang, Hsien-Yang Tsai, Mei-Ling Peng, Shi-Huang Lee, Siu-Fung Chau, Chen Yu Chen, Wai-Man Cheang, Shih-Jen Chen, Pui-Yan Kwok, Shih-Hwa Chiou, Mei-Yeh Jade Lu, and Shun-Ping Huang. Highly efficient capture approach for the identification of diverse inherited retinal disorders. NPJ Genomic Medicine, Jan 2024. URL: https://doi.org/10.1038/s41525-023-00388-3, doi:10.1038/s41525-023-00388-3. This article has 11 citations and is from a peer-reviewed journal.
(liu2024wholegenomesequencing pages 1-2): Xubing Liu, Fangyuan Hu, Daowei Zhang, Zhe Li, Jianquan He, Shenghai Zhang, Zhenguo Wang, Yingke Zhao, Jiawen Wu, Chen Liu, Chenchen Li, Xin Li, and Jihong Wu. Whole genome sequencing enables new genetic diagnosis for inherited retinal diseases by identifying pathogenic variants. NPJ Genomic Medicine, Jan 2024. URL: https://doi.org/10.1038/s41525-024-00391-2, doi:10.1038/s41525-024-00391-2. This article has 36 citations and is from a peer-reviewed journal.
(jordi2024limitedaddeddiagnostic pages 1-2): Jordi Maggi, Samuel Koller, Silke Feil, Ruxandra Bachmann-Gagescu, Christina Gerth-Kahlert, and Wolfgang Berger. Limited added diagnostic value of whole genome sequencing in genetic testing of inherited retinal diseases in a swiss patient cohort. International Journal of Molecular Sciences, Jun 2024. URL: https://doi.org/10.3390/ijms25126540, doi:10.3390/ijms25126540. This article has 14 citations.
(surl2024cliniciandrivenreanalysisof pages 1-2): Dongheon Surl, Dongju Won, Seung-Tae Lee, Christopher Seungkyu Lee, Junwon Lee, Hyun Taek Lim, Seung Ah Chung, Won Kyung Song, Min Kim, Sung Soo Kim, Saeam Shin, Jong Rak Choi, Riccardo Sangermano, Suk Ho Byeon, Kinga M. Bujakowska, and Jinu Han. Clinician-driven reanalysis of exome sequencing data from patients with inherited retinal diseases. JAMA Network Open, 7:e2414198, May 2024. URL: https://doi.org/10.1001/jamanetworkopen.2024.14198, doi:10.1001/jamanetworkopen.2024.14198. This article has 13 citations and is from a peer-reviewed journal.
(manley2023cellularandmolecular pages 19-20): Andrew Manley, Bahar I. Meshkat, Monica M. Jablonski, and T.J. Hollingsworth. Cellular and molecular mechanisms of pathogenesis underlying inherited retinal dystrophies. Biomolecules, 13:271, Feb 2023. URL: https://doi.org/10.3390/biom13020271, doi:10.3390/biom13020271. This article has 61 citations.
(gong2024infantilenystagmussyndrome—associated pages 2-4): Xiaoming Gong and Richard W. Hertle. Infantile nystagmus syndrome—associated inherited retinal diseases: perspectives from gene therapy clinical trials. Life, 14:1356, Oct 2024. URL: https://doi.org/10.3390/life14111356, doi:10.3390/life14111356. This article has 2 citations.
(sather2023clinicalcharacteristicsand pages 2-4): Richard Sather, Jacie Ihinger, Michael Simmons, Tahsin Khundkar, Glenn P. Lobo, and Sandra R. Montezuma. Clinical characteristics and genetic variants of a large cohort of patients with retinitis pigmentosa using multimodal imaging and next generation sequencing. International Journal of Molecular Sciences, 24:10895, Jun 2023. URL: https://doi.org/10.3390/ijms241310895, doi:10.3390/ijms241310895. This article has 12 citations.
(sather2023clinicalcharacteristicsand pages 1-2): Richard Sather, Jacie Ihinger, Michael Simmons, Tahsin Khundkar, Glenn P. Lobo, and Sandra R. Montezuma. Clinical characteristics and genetic variants of a large cohort of patients with retinitis pigmentosa using multimodal imaging and next generation sequencing. International Journal of Molecular Sciences, 24:10895, Jun 2023. URL: https://doi.org/10.3390/ijms241310895, doi:10.3390/ijms241310895. This article has 12 citations.
(sather2023clinicalcharacteristicsand media ad2e1a73): Richard Sather, Jacie Ihinger, Michael Simmons, Tahsin Khundkar, Glenn P. Lobo, and Sandra R. Montezuma. Clinical characteristics and genetic variants of a large cohort of patients with retinitis pigmentosa using multimodal imaging and next generation sequencing. International Journal of Molecular Sciences, 24:10895, Jun 2023. URL: https://doi.org/10.3390/ijms241310895, doi:10.3390/ijms241310895. This article has 12 citations.
(murro2023amultidisciplinaryapproach pages 5-7): Vittoria Murro, Sandro Banfi, Francesco Testa, Giancarlo Iarossi, Benedetto Falsini, Andrea Sodi, Sabrina Signorini, Achille Iolascon, Roberta Russo, Dario Pasquale Mucciolo, Roberto Caputo, Giacomo Maria Bacci, Sara Bargiacchi, Simona Turco, Stefania Fortini, and Francesca Simonelli. A multidisciplinary approach to inherited retinal dystrophies from diagnosis to initial care: a narrative review with inputs from clinical practice. Orphanet Journal of Rare Diseases, Jul 2023. URL: https://doi.org/10.1186/s13023-023-02798-z, doi:10.1186/s13023-023-02798-z. This article has 51 citations and is from a peer-reviewed journal.
(mack2023surveyofperspectives pages 4-6): Heather G. Mack, Alexis Ceecee Britten-Jones, Myra B. McGuinness, Fred K. Chen, John R. Grigg, Robyn V. Jamieson, Thomas L. Edwards, John De Roach, Fleur O’Hare, Keith R. Martin, and Lauren N. Ayton. Survey of perspectives of people with inherited retinal diseases on ocular gene therapy in australia. Gene Therapy, 30:336-346, Oct 2023. URL: https://doi.org/10.1038/s41434-022-00364-z, doi:10.1038/s41434-022-00364-z. This article has 19 citations and is from a peer-reviewed journal.
(gong2024infantilenystagmussyndrome—associated pages 16-17): Xiaoming Gong and Richard W. Hertle. Infantile nystagmus syndrome—associated inherited retinal diseases: perspectives from gene therapy clinical trials. Life, 14:1356, Oct 2024. URL: https://doi.org/10.3390/life14111356, doi:10.3390/life14111356. This article has 2 citations.
(duncan2024inheritedretinaldegenerations pages 2-4): Jacque L. Duncan, Angela Bowman, Amy Laster, Claire Gelfman, David G. Birch, Shannon E. Boye, Stephen P. Daiger, Lucian del Priore, Donald J. Zack, and James T. Handa. Inherited retinal degenerations and non-neovascular age-related macular degeneration: progress and unmet needs. Translational Vision Science & Technology, 13:28, Dec 2024. URL: https://doi.org/10.1167/tvst.13.12.28, doi:10.1167/tvst.13.12.28. This article has 11 citations and is from a peer-reviewed journal.
(manley2023cellularandmolecular pages 18-19): Andrew Manley, Bahar I. Meshkat, Monica M. Jablonski, and T.J. Hollingsworth. Cellular and molecular mechanisms of pathogenesis underlying inherited retinal dystrophies. Biomolecules, 13:271, Feb 2023. URL: https://doi.org/10.3390/biom13020271, doi:10.3390/biom13020271. This article has 61 citations.
(manley2023cellularandmolecular pages 8-10): Andrew Manley, Bahar I. Meshkat, Monica M. Jablonski, and T.J. Hollingsworth. Cellular and molecular mechanisms of pathogenesis underlying inherited retinal dystrophies. Biomolecules, 13:271, Feb 2023. URL: https://doi.org/10.3390/biom13020271, doi:10.3390/biom13020271. This article has 61 citations.
(manley2023cellularandmolecular pages 14-16): Andrew Manley, Bahar I. Meshkat, Monica M. Jablonski, and T.J. Hollingsworth. Cellular and molecular mechanisms of pathogenesis underlying inherited retinal dystrophies. Biomolecules, 13:271, Feb 2023. URL: https://doi.org/10.3390/biom13020271, doi:10.3390/biom13020271. This article has 61 citations.
(murro2023amultidisciplinaryapproach pages 3-5): Vittoria Murro, Sandro Banfi, Francesco Testa, Giancarlo Iarossi, Benedetto Falsini, Andrea Sodi, Sabrina Signorini, Achille Iolascon, Roberta Russo, Dario Pasquale Mucciolo, Roberto Caputo, Giacomo Maria Bacci, Sara Bargiacchi, Simona Turco, Stefania Fortini, and Francesca Simonelli. A multidisciplinary approach to inherited retinal dystrophies from diagnosis to initial care: a narrative review with inputs from clinical practice. Orphanet Journal of Rare Diseases, Jul 2023. URL: https://doi.org/10.1186/s13023-023-02798-z, doi:10.1186/s13023-023-02798-z. This article has 51 citations and is from a peer-reviewed journal.
(heon2023geneticsofretinal pages 4-5): MD Elise Héon, M Ajoy Vincent, and A Tayyib. Genetics of retinal degeneration in 2023. Canadian Eye Care Today, Feb 2023. URL: https://doi.org/10.58931/cect.2023.2122, doi:10.58931/cect.2023.2122. This article has 0 citations.
(weisschuh2024diagnosticgenomesequencing pages 1-2): Nicole Weisschuh, Pascale Mazzola, Theresia Zuleger, Karin Schaeferhoff, Laura Kühlewein, Friederike Kortüm, Dennis Witt, Alexandra Liebmann, Ruth Falb, Lisa Pohl, Milda Reith, Lara G Stühn, Miriam Bertrand, Amelie Müller, Nicolas Casadei, Olga Kelemen, Carina Kelbsch, Christoph Kernstock, Paul Richter, Francoise Sadler, German Demidov, Leon Schütz, Jakob Admard, Marc Sturm, Ute Grasshoff, Felix Tonagel, Tilman Heinrich, Fadi Nasser, Bernd Wissinger, Stephan Ossowski, Susanne Kohl, Olaf Riess, Katarina Stingl, and Tobias B Haack. Diagnostic genome sequencing improves diagnostic yield: a prospective single-centre study in 1000 patients with inherited eye diseases. Journal of Medical Genetics, 61:186-195, Sep 2024. URL: https://doi.org/10.1136/jmg-2023-109470, doi:10.1136/jmg-2023-109470. This article has 73 citations and is from a domain leading peer-reviewed journal.
(testa2024voretigeneneparvovecfor pages 1-2): Francesco Testa, Giacomo Bacci, Benedetto Falsini, Giancarlo Iarossi, Paolo Melillo, Dario Pasquale Mucciolo, Vittoria Murro, Anna Paola Salvetti, Andrea Sodi, Giovanni Staurenghi, and Francesca Simonelli. Voretigene neparvovec for inherited retinal dystrophy due to rpe65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice. Eye, 38:2504-2515, Apr 2024. URL: https://doi.org/10.1038/s41433-024-03065-6, doi:10.1038/s41433-024-03065-6. This article has 37 citations and is from a peer-reviewed journal.
(kvanta2024interimsafetyand pages 1-2): Anders Kvanta, Nalini Rangaswamy, Karen Holopigian, Christine Watters, Nicki Jennings, Melissa S. H. Liew, Chad Bigelow, Cynthia Grosskreutz, Marie Burstedt, Abinaya Venkataraman, Sofie Westman, Asbjörg Geirsdottir, Kalliopi Stasi, and Helder André. Interim safety and efficacy of gene therapy for rlbp1-associated retinal dystrophy: a phase 1/2 trial. Nature Communications, Sep 2024. URL: https://doi.org/10.1038/s41467-024-51575-4, doi:10.1038/s41467-024-51575-4. This article has 16 citations and is from a highest quality peer-reviewed journal.
(wang2024genereplacementtherapy pages 1-2): Jinyuan Wang, Jinlu Zhang, Shicheng Yu, Hongyan Li, Shaohong Chen, Jingting Luo, Haibo Wang, Yuxia Guan, Haihan Zhang, Shiyi Yin, Huili Wang, Heping Li, Junle Liu, Jingyuan Zhu, Qiong Yang, Ying Sha, Chuan Zhang, Yuhang Yang, Xuan Yang, Xifang Zhang, Xiuli Zhao, Likun Wang, Liping Yang, and Wen-guo Wei. Gene replacement therapy in bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial. Signal Transduction and Targeted Therapy, Apr 2024. URL: https://doi.org/10.1038/s41392-024-01806-3, doi:10.1038/s41392-024-01806-3. This article has 30 citations and is from a peer-reviewed journal.
(NCT00999609 chunk 1): Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis. Spark Therapeutics, Inc.. 2012. ClinicalTrials.gov Identifier: NCT00999609
(brar2023genetherapyfor pages 23-25): Anand Singh Brar, Deepika C. Parameswarappa, Brijesh Takkar, Raja Narayanan, Subhadra Jalali, Sohini Mandal, Kaoru Fujinami, and Srikanta Kumar Padhy. Gene therapy for inherited retinal diseases: from laboratory bench to patient bedside and beyond. Ophthalmology and Therapy, 13:21-50, Dec 2024. URL: https://doi.org/10.1007/s40123-023-00862-2, doi:10.1007/s40123-023-00862-2. This article has 46 citations and is from a peer-reviewed journal.
(NCT03872479 chunk 1): Single Ascending Dose Study in Participants With LCA10. Editas Medicine, Inc.. 2019. ClinicalTrials.gov Identifier: NCT03872479
(murro2023amultidisciplinaryapproach pages 7-8): Vittoria Murro, Sandro Banfi, Francesco Testa, Giancarlo Iarossi, Benedetto Falsini, Andrea Sodi, Sabrina Signorini, Achille Iolascon, Roberta Russo, Dario Pasquale Mucciolo, Roberto Caputo, Giacomo Maria Bacci, Sara Bargiacchi, Simona Turco, Stefania Fortini, and Francesca Simonelli. A multidisciplinary approach to inherited retinal dystrophies from diagnosis to initial care: a narrative review with inputs from clinical practice. Orphanet Journal of Rare Diseases, Jul 2023. URL: https://doi.org/10.1186/s13023-023-02798-z, doi:10.1186/s13023-023-02798-z. This article has 51 citations and is from a peer-reviewed journal.
(mack2023surveyofperspectives pages 2-3): Heather G. Mack, Alexis Ceecee Britten-Jones, Myra B. McGuinness, Fred K. Chen, John R. Grigg, Robyn V. Jamieson, Thomas L. Edwards, John De Roach, Fleur O’Hare, Keith R. Martin, and Lauren N. Ayton. Survey of perspectives of people with inherited retinal diseases on ocular gene therapy in australia. Gene Therapy, 30:336-346, Oct 2023. URL: https://doi.org/10.1038/s41434-022-00364-z, doi:10.1038/s41434-022-00364-z. This article has 19 citations and is from a peer-reviewed journal.
(marques2024currentmanagementof pages 1-2): João Pedro Marques, Nuno Ferreira, Natacha Moreno, Ana Marta, Sara Vaz-Pereira, Sérgio Estrela-Silva, José Costa, Ana Rocha Cardoso, Pedro Neves, Lilianne Duarte, Dália Meira, Joana Pires, Carlos Menezes, Filipa Rodrigues, Pedro Arede, André Coutinho, Diogo Cabral, Inês Coutinho, Miguel Ribeiro, Marta Macedo, Sérgio Brito, Filipe Isidro, Filipa Gomes Rodrigues, João Paulo Castro Sousa, Marco Marques, Raquel Martins, and Eduardo Silva. Current management of inherited retinal degenerations in portugal (ird-pt survey). Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-72589-4, doi:10.1038/s41598-024-72589-4. This article has 7 citations and is from a peer-reviewed journal.
(munir2024asystematicreview pages 10-12): Asad Munir, Salma Afsar, and Atta Ur Rehman. A systematic review of inherited retinal dystrophies in pakistan: updates from 1999 to april 2023. BMC Ophthalmology, Feb 2024. URL: https://doi.org/10.1186/s12886-024-03319-7, doi:10.1186/s12886-024-03319-7. This article has 18 citations and is from a peer-reviewed journal.
(munir2024asystematicreview pages 9-10): Asad Munir, Salma Afsar, and Atta Ur Rehman. A systematic review of inherited retinal dystrophies in pakistan: updates from 1999 to april 2023. BMC Ophthalmology, Feb 2024. URL: https://doi.org/10.1186/s12886-024-03319-7, doi:10.1186/s12886-024-03319-7. This article has 18 citations and is from a peer-reviewed journal.
(kao2024highlyefficientcapture pages 2-2): Hsiao-Jung Kao, Ting-Yi Lin, Feng-Jen Hsieh, Jia-Ying Chien, Erh-Chan Yeh, Wan-Jia Lin, Yi-Hua Chen, Kai-Hsuan Ding, Yu Yang, Sheng-Chu Chi, Ping-Hsing Tsai, Chih-Chien Hsu, De-Kuang Hwang, Hsien-Yang Tsai, Mei-Ling Peng, Shi-Huang Lee, Siu-Fung Chau, Chen Yu Chen, Wai-Man Cheang, Shih-Jen Chen, Pui-Yan Kwok, Shih-Hwa Chiou, Mei-Yeh Jade Lu, and Shun-Ping Huang. Highly efficient capture approach for the identification of diverse inherited retinal disorders. NPJ Genomic Medicine, Jan 2024. URL: https://doi.org/10.1038/s41525-023-00388-3, doi:10.1038/s41525-023-00388-3. This article has 11 citations and is from a peer-reviewed journal.
(jordi2024limitedaddeddiagnostic pages 8-9): Jordi Maggi, Samuel Koller, Silke Feil, Ruxandra Bachmann-Gagescu, Christina Gerth-Kahlert, and Wolfgang Berger. Limited added diagnostic value of whole genome sequencing in genetic testing of inherited retinal diseases in a swiss patient cohort. International Journal of Molecular Sciences, Jun 2024. URL: https://doi.org/10.3390/ijms25126540, doi:10.3390/ijms25126540. This article has 14 citations.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

1.1 Overview (current understanding)

1.2 Major clinical subtypes / synonyms used in practice

1.3 Key identifiers and terminologies

1.4 Evidence source type

2. Etiology

2.1 Primary causes

2.2 Genetic risk factors (causal genes; examples from recent cohorts)

2.3 Variant classes contributing to IRD and unsolved cases (2023–2024)

2.4 Modifier genes / protective factors / gene–environment interactions

3. Phenotypes

3.1 Core symptom/sign spectrum

3.2 Cohort-based phenotype frequencies (example: RP clinic cohort)

3.3 Phenotype characteristics (onset, progression)

3.4 Quality of life and functional burden

3.5 Suggested HPO terms (examples)

4. Genetic/Molecular Information

4.1 Causal genes (examples; not exhaustive)

4.2 Pathogenic variant types and frequency considerations

4.3 Somatic vs germline

4.4 Epigenetics

5. Environmental Information

6. Mechanism / Pathophysiology

6.1 Affected structures and key causal chains

6.2 Cell types (CL suggestions)

6.3 Anatomical structures (UBERON suggestions)

6.4 Pathway/process ontology suggestions (GO terms; examples)

6.5 Recent multi-omics / translational advances (2024)

7. Anatomical Structures Affected

8. Temporal Development (Natural history)

9. Inheritance and Population

9.1 Epidemiology (recent and cohort-based)

9.2 Population genetics and consanguinity

10. Diagnostics

10.1 Clinical and functional testing (recommended workup)

10.2 Genetic testing strategy and yields (2023–2024)

10.3 Differential diagnosis

11. Outcome / Prognosis

11.1 Vision-related prognosis

11.2 Economic and societal burden (recent data)

12. Treatment

12.1 Approved gene therapy (real-world implementation)

12.2 Landmark and emerging interventional trials (2024)

12.3 Clinical trials and real-world endpoints

12.4 In vivo genome editing (recent implementation example)

13. Prevention

13.1 Primary prevention

13.2 Secondary/tertiary prevention

14. Other Species / Natural Disease

15. Model Organisms

Recent developments and real-world implementation highlights (2023–2024 synthesis)

Evidence summary tables

Key URLs (recent, prioritized)

Artifacts